DexTech Medical AB (XSAT:DEX) Cash Flow from Operations: kr-1.33 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:DEX DexTech Medical AB XSAT:DEX
23 GF Score
Price kr10.30
! 3 Warning Signs
View Full Analysis

What is DexTech Medical AB Cash Flow from Operations?

DexTech Medical AB XSAT:DEX -0.96% 23 Cash Flow from Operations is kr-1.33 Mil as of Mar. 2026. GuruFocus rates XSAT:DEX with a GF Score™ of 23/100. The stock has 3 warning signs investors should review.

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Mar. 2026, DexTech Medical AB's Net Income From Continuing Operations was kr-1.73 Mil. Its Depreciation, Depletion and Amortization was kr0.00 Mil. Its Change In Working Capital was kr0.00 Mil. Its cash flow from deferred tax was kr0.00 Mil. Its Cash from Discontinued Operating Activities was kr0.00 Mil. Its Asset Impairment Charge was kr0.00 Mil. Its Stock Based Compensation was kr0.00 Mil. And its Cash Flow from Others was kr1.24 Mil. In all, DexTech Medical AB's Cash Flow from Operations for the three months ended in Mar. 2026 was kr-0.49 Mil.


DexTech Medical AB  (XSAT:DEX) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

DexTech Medical AB's net income from continuing operations for the three months ended in Mar. 2026 was kr-1.73 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

DexTech Medical AB's depreciation, depletion and amortization for the three months ended in Mar. 2026 was kr0.00 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

DexTech Medical AB's change in working capital for the three months ended in Mar. 2026 was kr0.00 Mil. It means DexTech Medical AB's working capital {id_Q12} from Dec. 2025 to Mar. 2026 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

DexTech Medical AB's cash flow from deferred tax for the three months ended in Mar. 2026 was kr0.00 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

DexTech Medical AB's cash from discontinued operating Activities for the three months ended in Mar. 2026 was kr0.00 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

DexTech Medical AB's asset impairment charge for the three months ended in Mar. 2026 was kr0.00 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

DexTech Medical AB's stock based compensation for the three months ended in Mar. 2026 was kr0.00 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

DexTech Medical AB's cash flow from others for the three months ended in Mar. 2026 was kr1.24 Mil.


DexTech Medical AB Cash Flow from Operations Related Terms


DexTech Medical AB Cash Flow from Operations Historical Data

* Premium members only.

The historical data trend for DexTech Medical AB's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DexTech Medical AB Cash Flow from Operations Chart

DexTech Medical AB Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.00 -2.00 -1.55 -0.81 -1.11

DexTech Medical AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.20 -0.30 0.19 -0.73 -0.49
XSAT:DEX
23GF Score
DexTech Medical AB XSAT:DEX
Cash Flow from Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DexTech Medical AB Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

DexTech Medical AB's Cash Flow from Operations for the fiscal year that ended in Jun. 2025 is calculated as:

DexTech Medical AB's Cash Flow from Operations for the quarter that ended in Mar. 2026 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-1.33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Operations of kr-1.33 Mil mean?
DexTech Medical AB (XSAT:DEX) has a Cash Flow from Operations of kr-1.33 Mil as of Mar. 2026. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for DexTech Medical AB and its competitors.
Is DexTech Medical AB's Cash Flow from Operations too high?
DexTech Medical AB's current Cash Flow from Operations is kr-1.33 Mil. Overall, DexTech Medical AB has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does DexTech Medical AB's Cash Flow from Operations compare to VRTX and REGN?
DexTech Medical AB's Cash Flow from Operations of kr-1.33 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Operations for a Biotechnology company?
A good Cash Flow from Operations depends on the Biotechnology industry context. However, Cash Flow from Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Operations mean?
A high Cash Flow from Operations can signal that a stock is expensive relative to its fundamentals. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for DexTech Medical AB and its competitors. DexTech Medical AB's current Cash Flow from Operations is kr-1.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexTech Medical AB stock overvalued right now?
DexTech Medical AB (XSAT:DEX) has a current Cash Flow from Operations of kr-1.33 Mil. The current Cash Flow from Operations is kr-1.33 Mil. DexTech Medical AB's overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Operations calculated?
Cash Flow from Operations is calculated from a company's financial statements. For DexTech Medical AB (XSAT:DEX), the current Cash Flow from Operations is kr-1.33 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DexTech Medical AB Business Description

Address Dag Hammarskjolds Vag 34A, Uppsala, SWE, 752 37
DexTech Medical AB is a Swedish research company specializing in drug development for urological oncology, with a prominent focus on prostate cancer. The company develops drug candidates using a proprietary carbohydrate platform, advancing treatments aimed at castration-resistant prostate cancer and related conditions. Its operations center on research, development, and licensing of these drug candidates. It has four drug candidates: OsteoDex, SomaDex, PSMA-binding conjugates, and GuaDex.
23GF Score

Get the complete analysis for XSAT:DEX

Cash Flow from Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr10.30
Price